Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Adverse effects
[72] RCT	183 people	Adverse-event incidence after 24 weeks 7/92 (8%) with mesoglycan 6/91 (7%) with placebo	Significance not assessed